病毒-受体相互作用与病毒中和:溶瘤病毒开发的启示。

IF 6.7
Oncolytic Virotherapy Pub Date : 2020-03-06 eCollection Date: 2020-01-01 DOI:10.2147/OV.S186337
Nadishka Jayawardena, John T Poirier, Laura N Burga, Mihnea Bostina
{"title":"病毒-受体相互作用与病毒中和:溶瘤病毒开发的启示。","authors":"Nadishka Jayawardena, John T Poirier, Laura N Burga, Mihnea Bostina","doi":"10.2147/OV.S186337","DOIUrl":null,"url":null,"abstract":"<p><p>Oncolytic viruses (OVs) are replication competent agents that selectively target cancer cells. After penetrating the tumor cell, viruses replicate and eventually trigger cell lysis, releasing the new viral progeny, which at their turn will attack and kill neighbouring cells. The ability of OVs to self-amplify within the tumor while sparing normal cells can provide several advantages including the capacity to encode and locally produce therapeutic protein payloads, and to prime the host immune system. OVs targeting of cancer cells is mediated by host factors that are differentially expressed between normal tissue and tumors, including viral receptors and internalization factors. In this review article, we will discuss the evolution of oncolytic viruses that have reached the stage of clinical trials, their mechanisms of oncolysis, cellular receptors, strategies for targeting cancers, viral neutralization and developments to bypass virus neutralization.</p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"9 ","pages":"1-15"},"PeriodicalIF":6.7000,"publicationDate":"2020-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/3f/ov-9-1.PMC7064293.pdf","citationCount":"0","resultStr":"{\"title\":\"Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development.\",\"authors\":\"Nadishka Jayawardena, John T Poirier, Laura N Burga, Mihnea Bostina\",\"doi\":\"10.2147/OV.S186337\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Oncolytic viruses (OVs) are replication competent agents that selectively target cancer cells. After penetrating the tumor cell, viruses replicate and eventually trigger cell lysis, releasing the new viral progeny, which at their turn will attack and kill neighbouring cells. The ability of OVs to self-amplify within the tumor while sparing normal cells can provide several advantages including the capacity to encode and locally produce therapeutic protein payloads, and to prime the host immune system. OVs targeting of cancer cells is mediated by host factors that are differentially expressed between normal tissue and tumors, including viral receptors and internalization factors. In this review article, we will discuss the evolution of oncolytic viruses that have reached the stage of clinical trials, their mechanisms of oncolysis, cellular receptors, strategies for targeting cancers, viral neutralization and developments to bypass virus neutralization.</p>\",\"PeriodicalId\":19491,\"journal\":{\"name\":\"Oncolytic Virotherapy\",\"volume\":\"9 \",\"pages\":\"1-15\"},\"PeriodicalIF\":6.7000,\"publicationDate\":\"2020-03-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/3f/ov-9-1.PMC7064293.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncolytic Virotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/OV.S186337\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncolytic Virotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OV.S186337","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

肿瘤溶解病毒(OV)是一种具有复制能力的病毒,可选择性地针对癌细胞。穿透肿瘤细胞后,病毒复制并最终引发细胞裂解,释放出新的病毒后代,进而攻击并杀死邻近细胞。OVs 能够在肿瘤内自我扩增,而不损伤正常细胞,因此具有多种优势,包括编码和在局部产生治疗性蛋白质有效载荷的能力,以及增强宿主免疫系统的能力。OVs对癌细胞的靶向作用由宿主因子介导,而宿主因子在正常组织和肿瘤之间有不同的表达方式,包括病毒受体和内化因子。在这篇综述文章中,我们将讨论已进入临床试验阶段的溶瘤病毒的演变、它们的溶瘤机制、细胞受体、靶向癌症的策略、病毒中和以及绕过病毒中和的发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development.

Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development.

Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development.

Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development.

Oncolytic viruses (OVs) are replication competent agents that selectively target cancer cells. After penetrating the tumor cell, viruses replicate and eventually trigger cell lysis, releasing the new viral progeny, which at their turn will attack and kill neighbouring cells. The ability of OVs to self-amplify within the tumor while sparing normal cells can provide several advantages including the capacity to encode and locally produce therapeutic protein payloads, and to prime the host immune system. OVs targeting of cancer cells is mediated by host factors that are differentially expressed between normal tissue and tumors, including viral receptors and internalization factors. In this review article, we will discuss the evolution of oncolytic viruses that have reached the stage of clinical trials, their mechanisms of oncolysis, cellular receptors, strategies for targeting cancers, viral neutralization and developments to bypass virus neutralization.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信